Autoinflammatory Diseases: An Update of Clinical and Genetic Aspects

Q. Yao; D. E. Furst


Rheumatology. 2008;47(7):946-951. 

In This Article


Although the AIDs share some clinical features, such as (i) periodic fever of variable duration, (ii) hereditary and recurrent and (iii) elevated acute-phase proteins, there are differences that may be used to differentiate one from another ( Table 2 ).

Treatment, too, has both similarities and differences, so that colchicine is the treatment of first choice for FMF, glucocorticoids seem best suited for TRAPS, TNF-α blockade and IL-1ra may work for HIDS and IL-1ra seems effective for CAPS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: